Skip to Primary Navigation

Skip to main content

SEC puts concept of ‘shadow insider trading’ to test in court action

SEC building
Photo: AaronP/Bauer-Griffin/GC Images

Julie DiMauro

6 min read

Biotech executive Matthew Panuwat bought options on stock of another company he was not privy to inside information about. Was it insider trading?

he bet. The
, , , , , , , , , , ,

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

Start free trial
Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience